The FDA has approved guselkumab (TREMFYA®) for moderately to severely active Crohn’s disease, supported by Phase 3 trial data showing clinical and endoscopic superiority over ustekinumab.
Chomps beef and turkey sticks pulled from shelves in multi-state recall after metal fragments discovered; manufacturer urges consumers to check lot codes and return affected products for refund.
The FDA warns of serious health risks associated with non-medical use of nitrous oxide, highlighting neurological damage, thromboembolic events, and death.
The FDA has selected influenza vaccine strains for the 2025 to 2026 U.S. flu season, maintaining consistency with prior formulations while incorporating updated epidemiologic and antigenic data to optimize protection.
The FDA's 2025 pulse oximetry guidance introduces stricter accuracy standards, larger study cohorts, and objective skin pigmentation assessment to address measurement bias in darker-skinned patients.